Literature DB >> 8554983

Oestrogen receptor: a stable phenotype in breast cancer.

J F Robertson1.   

Abstract

Oestrogen receptor (ER) expression in breast cancer is regarded as a phenotype that may change during the natural history of the disease or during endocrine therapy. It has been suggested that in up to 70% of tumours that show acquired resistance the mechanism may be changed in ER status from positive to negative. This paper proposes an alternative hypothesis that ER expression in a stable phenotype in breast cancer. The paper reviews the literature on ER expression during the natural history of breast cancer in patients and also presents data on the effect of endocrine therapy on ER expression. If the alternative hypothesis is true it has important implications for treatment from chemoprevention to acquired endocrine resistance in advanced disease. Equally, if the hypothesis is true, attempts to develop laboratory models of endocrine resistance where ER-positive tumours become ER negative need to be re-evaluated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8554983      PMCID: PMC2074280          DOI: 10.1038/bjc.1996.2

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  98 in total

1.  Cellular and molecular events in loss of estrogen sensitivity in ZR-75-1 and T-47-D human breast cancer cells.

Authors:  R J Daly; P D Darbre
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

2.  Estrogen receptors in ductal carcinoma in situ of breast.

Authors:  M Malafa; B Chaudhuri; N R Thomford; P K Chaudhuri
Journal:  Am Surg       Date:  1990-07       Impact factor: 0.688

3.  Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions.

Authors:  C S Murphy; J J Pink; V C Jordan
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

4.  Oestrogen receptors, cellularity, elastosis and menstrual status in human breast cancer.

Authors:  J R Masters; R A Hawkins; K Sangster; W Hawkins; I I Smith; A A Shivas; M M Roberts; A P Forrest
Journal:  Eur J Cancer       Date:  1978-03       Impact factor: 9.162

5.  Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer.

Authors:  W A Knight; R B Livingston; E J Gregory; W L McGuire
Journal:  Cancer Res       Date:  1977-12       Impact factor: 12.701

6.  Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study.

Authors:  D D Giri; S A Dundas; J F Nottingham; J C Underwood
Journal:  Histopathology       Date:  1989-12       Impact factor: 5.087

7.  Estrogen receptor assay in primary breast cancer and early recurrence of the disease.

Authors:  P V Maynard; R W Blamey; C W Elston; J L Haybittle; K Griffiths
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

8.  Variant human breast tumor estrogen receptor with constitutive transcriptional activity.

Authors:  S A Fuqua; S D Fitzgerald; G C Chamness; A K Tandon; D P McDonnell; Z Nawaz; B W O'Malley; W L McGuire
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

9.  Reproducibility of measurements of oestrogen-receptor concentration in breast cancer.

Authors:  R A Hawkins; A Hill; B Freedman; S M Gore; M M Roberts; A P Forrest
Journal:  Br J Cancer       Date:  1977-09       Impact factor: 7.640

10.  Oestrogen receptors and the response to endocrine therapy in advanced breast cancer.

Authors:  M M Roberts; R D Rubens; R J King; R A Hawkins; R R Millis; J L Hayward; A P Forrest
Journal:  Br J Cancer       Date:  1978-09       Impact factor: 7.640

View more
  23 in total

Review 1.  Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.

Authors:  R I Nicholson; I R Hutcheson; H E Jones; S E Hiscox; M Giles; K M Taylor; J M W Gee
Journal:  Rev Endocr Metab Disord       Date:  2007-09       Impact factor: 6.514

2.  Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer.

Authors:  Congwen Wei; Yuan Cao; Xiaoli Yang; Zirui Zheng; Kai Guan; Qiang Wang; Yanhong Tai; Yanhong Zhang; Shengli Ma; Ye Cao; Xiaoxing Ge; Changzhi Xu; Jia Li; Hui Yan; Youguo Ling; Ting Song; Lin Zhu; Buchang Zhang; Quanbin Xu; Chengjin Hu; Xiu-wu Bian; Xiang He; Hui Zhong
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-21       Impact factor: 11.205

3.  Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.

Authors:  Ines Barone; Lauren Brusco; Guowei Gu; Jennifer Selever; Amanda Beyer; Kyle R Covington; Anna Tsimelzon; Tao Wang; Susan G Hilsenbeck; Gary C Chamness; Sebastiano Andò; Suzanne A W Fuqua
Journal:  J Natl Cancer Inst       Date:  2011-03-29       Impact factor: 13.506

4.  Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells.

Authors:  S Cariou; J C Donovan; W M Flanagan; A Milic; N Bhattacharya; J M Slingerland
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

Review 5.  Tamoxifen resistance in breast cancer: elucidating mechanisms.

Authors:  L C Dorssers; S Van der Flier; A Brinkman; T van Agthoven; J Veldscholte; E M Berns; J G Klijn; L V Beex; J A Foekens
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  LCC15-MB: a vimentin-positive human breast cancer cell line from a femoral bone metastasis.

Authors:  E W Thompson; V Sung; M Lavigne; K Baumann; N Azumi; A D Aaron; R Clarke
Journal:  Clin Exp Metastasis       Date:  1999-05       Impact factor: 5.150

Review 7.  Differentiation and cancer in the mammary gland: shedding light on an old dichotomy.

Authors:  O W Petersen; L Rønnov-Jessen; V M Weaver; M J Bissell
Journal:  Adv Cancer Res       Date:  1998       Impact factor: 6.242

Review 8.  Estrogen receptor alpha in human breast cancer: occurrence and significance.

Authors:  S Ali; R C Coombes
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

9.  Genetic screening reveals an essential role of p27kip1 in restriction of breast cancer progression.

Authors:  Yuhui Yuan; Li Qin; Dan Liu; Ray-Chang Wu; Paola Mussi; Suoling Zhou; Zhou Songyang; Jianming Xu
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

10.  Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix.

Authors:  Yiyun Zhang; Huiping Zhao; Szilard Asztalos; Michael Chisamore; Yasmin Sitabkhan; Debra A Tonetti
Journal:  Mol Cancer Res       Date:  2009-04       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.